The buildup of amyloid in certain organs can enlarge them and affect the way they work. For example: The cancer cells in people with WM are similar to those in multiple myeloma and non-Hodgkin ...

FDA grants fast track designation to azer-cel, an allogeneic CAR T-cell therapy, for relapsed or refractory diffuse large ...

When she got home, she threw up and collapsed into bed, falling asleep around 5 p.m. The following morning, she went to urgent care, where doctors took an X-ray of her chest. It was the same day they ...

Sanofi’s move for Dren Bio’s clinical asset boosts its immunology-focused strategy of becoming a leader in the field.

Through the Dren Bio deal, SNY intends to expand its immunology pipeline and establish itself as a leading immunology company ...

Synthetic biology company bit.bio has repositioned its business model to focus on its cell manufacturing strengths, ...

Golidocitinib is a JAK1 only inhibitor approved for the treatment of relapsed or refractory PTCL The combination of ...

In the latest move to cement its “immunology powerhouse” status, Sanofi is handing ove | The CD20-directed antibody, dubbed ...

Under the terms of the merger agreement, Sanofi will acquire DR-0201 through the acquisition of the Dren Bio affiliate ...

Sanofi is buying an immunology drug from Dren Bio, Inc. for up to $1.9 billion, in a deal it said will help it become a ...

Century Therapeutics has joined the onslaught of cell therapy biotechs taking hits, discontinuing a phase 1 cancer study to ...

Preclinical pipeline re-prioritization to focus on four potentially transformative programs to advance toward clinic, led by CNTY-308 in ...